Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.

Journal of cardiac failure - 1 Apr 2012

Talameh Jasmine A, McLeod Howard L, Adams Kirkwood F, Patterson J Herbert

Abstract excerpt

BACKGROUND: The combination of angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic receptor blockers remains the essential component of heart failure (HF) pharmacotherapy. However, individual patient responses to these pharmacotherapies vary widely. The variability in response cannot be explained entirely by clinical characteristics, and genetic variation may play a role. The purpose of this review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Angiotensin-Converting Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Deletion

Share to Heart Failure

Share to Metoprolol

Share to Mutagenesis, Insertional

Share to Precision Medicine

Share to Receptors, Adrenergic, beta-1

Source

Identifiers

PMID: 22464776
DOI: 10.1016/j.cardfail.2012.01.002

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.PMID 22464776Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical ReviewSemantic proximity Read ↗

Pharmacogenetics in heart failure: how it will shape the future.Semantic proximity Read ↗

Heart failure pharmacogenetics: past, present, and future.Semantic proximity Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read ↗

Pharmacogenetics of heart failure.Semantic proximity Read ↗

Genetics and pharmacogenetics in heart failure.Semantic proximity Read ↗

Pharmacogenomics in cardiac therapy: Personalizing treatment for heart healthSemantic proximity Read ↗

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.